Skip to content
Peptilyze
CompoundsShopsCompareMarketLab testsGuidesMethod

Peptides · Reference article

BPC-157 Evidence: Human Studies, Brain Claims and FDA Status

What is shown for BPC-157: three tiny human reports, one research group behind most animal work, no cognition data in people, and where FDA and WADA stand.

Published · Updated · Rests on: 1 systematic review of human studies (3 studies, n=30), 3 human pilot reports, 4 ClinicalTrials.gov records, a 234-record PubMed author count, 9 rodent brain papers, FDA and WADA documents, 1 preprint

This is a reference article, not a price comparison. Peptilyze compares prices of research peptides; it sells nothing and gives no medical advice. Every claim is numbered and listed under Sources.

Key points

  • A 2026 systematic review found three human studies of BPC-157 in total, 30 people, none with a control group, and rated the certainty of evidence “very low” [9].
  • Of 234 PubMed records matching BPC-157 on 2026-11-08, P. Sikirić of the Zagreb group is first or last author on 148 (63%) and an author on 176 (75%) [1].
  • The brain and dopamine work is rodent work, mostly from that group. We found no human cognition data and no test of cognitive enhancement in healthy animals [16][17][20].
  • No large randomized trial exists. The largest registered controlled trial plans 120 participants, is recruiting and has no results [13].
  • BPC-157 is not an approved medicine in the US and is prohibited in sport under WADA’s non-approved-substances class [9][29].

What BPC-157 is and where it came from

BPC-157 is a synthetic fragment of 15 amino acids (sequence GEPPPGKPADDAGLV) [3]. It is one of the compounds we compare on Peptilyze (/compounds/bpc-157/); this article covers evidence only.

An early paper in the record set is a 1993 overview by Sikirić and colleagues in Zagreb. It describes a stomach-juice protein called “BPC” and a 15-amino-acid fragment, BPC 157, “thought to be essential for its activity” [2]. The name stands for “body protection compound”. The group proposed that the stomach coordinates protection of other organs under stress [2].

How large the research base is, and who wrote it

We searched PubMed on 2026-11-08 for BPC-157, BPC157 or “body protection compound” in titles and abstracts. It returned 234 records from 1992 to 2026, 54 of them reviews [1]. We matched author names programmatically after removing diacritics.

Measure Records Share of 234
Sikirić first author 46 20%
Sikirić last author 103 44%
Sikirić first or last 148 63%
Sikirić anywhere in author list 176 75%

Among the 180 non-review records, Sikirić is first or last on 119 and an author on 143 [1]. Other groups do publish: Chang and Pang reported effects on tendon fibroblasts, Hsieh and Pang on blood-vessel growth, and a separate team on toxicology and pharmacokinetics in animals [32][33][34][35]. The count is a title-and-abstract search, so it misses papers that never use these terms. The Zagreb papers we read declare no conflict of interest [16][17][23].

Reviewers outside that group describe the evidence as mostly preclinical: a 2025 systematic review of orthopaedic use found 35 preclinical studies and one clinical study [10], and a 2026 review of rodent ischemia work calls it “hypothesis-generating”, with short observation periods and single-administration designs [37].

What the human studies show

We opened every human study we could find. All three come from one first author, E. Lee, at private clinics in Florida, and none had a control group [6][7][8][9].

Study Design Size Reported result
Lee and Padgett 2021 [6] Retrospective chart review with phone follow-up; knee pain of mixed causes 17 treated, 16 reached; 12 had BPC-157 alone, 4 had it with thymosin beta-4 14 of 16 reported relief; no validated function scores
Lee, Walker and Ayadi 2024 [7] Described as a pilot; interstitial cystitis in women who had not responded to pentosan polysulfate 12 women, mean age 58.3 10 of 12 reported complete symptom resolution on a patient-rated scale; no adverse events reported
Lee and Burgess 2025 [8] Prospective safety pilot; blood work and vital signs over three days 2 adults (58 and 68), both with prior exposure No change in blood markers for heart, liver, kidney, thyroid or glucose; no side effects reported

The 2026 systematic review (searches to 1 June 2026, PROSPERO CRD420261406325) included these three studies, n=30, and judged all of poor methodological quality with “very low” certainty because of risk of bias, indirectness and imprecision [9]. A 2025 HSS Journal review counted only the knee study as clinical and found “no clinical safety data” [10]. A 2026 Pharmaceutics review describes the same three pilots as uncontrolled, none using standardized pharmaceutical preparations [11]. PubMed lists no conflicts of interest for any of the three [6][7][8].

None of the three measured cognition, mood or any brain outcome.

Is there a large randomized trial?

No. A ClinicalTrials.gov search on 2026-11-08 for BPC-157, BPC157, pentadecapeptide and Bepecin returned four interventional records [12][13][14][15]:

Record Design Planned size Status
NCT02637284, PharmaCotherapia d.o.o. [12] Phase 1, healthy volunteers 18 to 35, randomized, quadruple-masked, placebo-controlled; safety and pharmacokinetics 42 Status “unknown”, start 2015-10, no results
NCT07437547, Hudson Biotech [13] Phase 2, randomized, double-blind, placebo-controlled; MRI-confirmed grade II hamstring strain 120 Recruiting, started 2026-02-02, primary completion estimated 2027-02, no results
NCT07803250, University of Arkansas [14] Phase 1 pilot, randomized, blinded, sham-controlled; after rotator cuff repair 30 listed (text says 20) Not yet recruiting, start estimated 2027-01
NCT07752381, Parlay Wellness with Citruslabs [15] Single-group study of a consumer product, 8 weeks 40 Completed, no results posted

Two sponsors are companies. None of the four lists a cognitive primary outcome. The Phase 1 record is the only one with a masked placebo group in healthy people, and we found no published report of it.

The one program that reached trials: PL 14736 and PL-10

The Zagreb group’s papers call BPC 157 by development codes PL-10, PLD-116 and PL 14736 and name Pliva, Croatia [3]. A 2006 review says it was “safe in clinical trials for inflammatory bowel disease” [3]. A 2012 review says it was “so far only tested in clinical phase II” [4]. A 2024 review by the group cites “ulcerative colitis, phase II, no side effects” [5].

We could not verify any of this independently. We found no published phase 2 results, the abstracts give no trial size, and ClinicalTrials.gov searches for “PL 14736” and “PL-10” returned no BPC-157 record. A 2026 independent review states there is “no completed Phase II clinical trial” [11]. Our reading: a ulcerative-colitis program is described by its proponents, with no results we could open. We did not open the conference abstracts that web searches surfaced because the host sites blocked automated access.

What animal work says about the brain, dopamine and neuroprotection

Rodent findings exist across several areas. We read these abstracts:

  • Dopamine. In rats, BPC 157 reduced stereotyped behaviour caused by amphetamine and the supersensitivity that follows haloperidol; in mice it reduced catalepsy from antipsychotics [18][19]. These are effects that counter drug-driven dopamine disturbances. They do not show a stimulant or focus-enhancing action.
  • Serotonin. A 2004 rat study (Tohyama, Sikirić and Diksic, with US NIH support) found regional changes in serotonin synthesis; the authors said the mechanism could not be determined [20].
  • Stroke-like injury. In rats with temporary carotid clamping, a 2020 study reported reduced hippocampal damage and recovery on a water-maze memory test [17]. A 2010 study in mice reported less damage after traumatic brain injury [21].
  • Mood and anxiety. A 2000 study reported antidepressant-like results in rat swimming and stress tests [38]. A 2001 study reported anxiolytic-like behaviour [39].
  • Cognition. We found two rodent papers that touch cognition. One was the hippocampal injury study above [17]; the other, a 2022 ketamine “schizophrenia-like” model, reported BPC 157 counteracting a ketamine-induced recognition deficit [40]. Both are injury or drug models, not healthy animals.
  • Enzyme assay. A 2026 test-tube study found BPC-157 weakly inhibits acetylcholinesterase, with an IC50 of 2.80 mM, which the authors call “significantly lower potency” than clinical inhibitors [22].

Of 33 non-review PubMed records whose titles mention brain, nervous-system or behaviour terms, Sikirić is first or last author on 28 and an author on 32; the exception is a 2019 study on cultured enteric neurons [1]. Our title-term filter is a rough one. The group’s own reviews propose a gut-brain role for BPC 157 [23]. That is a hypothesis in rodents, not a human finding.

Regulatory status

United States (checked 2026-11-08). We found no approved medicine containing BPC-157; two systematic reviews (2025, 2026) state it lacks approval [9][10]. Our openFDA Drugs@FDA queries for “BPC” returned no match, a weak check [30]. FDA’s compounding page (current as of 2026-04-22) lists BPC-157 among substances whose nominations were withdrawn and which were previously in category 2, and says compounded products “may pose risk for immunogenicity for certain routes of administration” and raise impurity and characterization questions [24]. FDA’s 14 May 2026 category document lists BPC-157 in none of its three categories [25].

On 23 July 2026 FDA’s Pharmacy Compounding Advisory Committee considered BPC-157. FDA’s briefing proposed that BPC-157 free base and acetate not be added to the 503A bulks list; FDA went ahead despite the nominators’ withdrawals [26][27]. ABC News reported an 8-6 vote in favour, one abstention, describing it as non-binding and needing FDA sign-off, with rulemaking that “can take up to a year” [28][41]. We found no final FDA decision in the sources we could open. We did not open FDA’s BPC-157 substance briefing.

Sport. WADA’s 2026 Prohibited List, in force 1 January 2026, places “any pharmacological substance” without government approval for human therapeutic use in S0, prohibited at all times, and names BPC-157 [29]. We did not open the 2027 list.

EU, UK, Germany. Not checked: we did not search EMA, MHRA or BfArM registers and found no regulator statement on BPC-157.

“Research use only.” This is a seller’s label, not a regulatory category. In a 31 March 2026 warning letter to a seller of other peptides (not naming BPC-157), FDA said such labels did not settle intended use when website evidence showed human use [42].

Quality and identity of unregulated products

A 2026 preprint (not peer reviewed) analysed 6,441 samples from a public independent testing dataset across 14 peptides, BPC-157 included. Depending on the standard, 41.6% to 71.1% failed basic quality criteria and 15% had measurable endotoxin; the abstract gives no BPC-157-only result [31]. A 2017 anti-doping laboratory paper identified BPC 157 in confiscated vials and built a urine test [36]. We found no peer-reviewed purity study of BPC-157 products alone.

Risks and unknowns

  • Human safety. The three pilots reported no adverse events in 30 people, without controls and with short follow-up [9]. Absence of reports in such studies is weak safety evidence.
  • Animal toxicology. A separate team reported no serious toxicity in mice, rats, rabbits and dogs, with mild local irritation and a creatinine fall in dogs at the top of the tested range that reversed after withdrawal [34]. Half-life is under 30 minutes in rats and dogs [35].
  • Theoretical concerns. BPC-157 promotes blood-vessel growth in cell and rat studies [32]. A 2026 review lists “pathological angiogenesis” and “carcinogenesis” among potential risks of unapproved peptides; it cites no human cases for BPC-157 [43].
  • Product quality. Low purity, measured amounts that differ from labels, and endotoxin are documented across gray-market peptides generally [31].
  • Not studied. Long-term use, pregnancy, children, interactions with psychiatric drugs, effects on cognition in healthy adults, and independent replication of the brain findings.

What the source post claims, and how it holds up

The @dex7official post, “THE ONLY TRUE COGNITIVE ENHANCEMENT TIER LIST (NO COPES EDITION)” (2026-10-20), places BPC-157 in its lowest tier, F. The image also shows a bottle labelled “Restore BPC” there [44]. The post offers no reasoning; its tiers rank many unrelated drugs [44]. Our wider tier-list evidence check covers the full list.

Claim Verdict Basis
BPC-157 belongs at the bottom for cognitive enhancement Partly supported No human cognition data exist [9][10], which fits a low ranking, but a ranking implies a comparison no source makes
A “Restore BPC” product delivers what BPC-157 research studied Could not verify We did not see its contents or testing; unregulated products vary widely [31]
Brain-protective or dopamine-acting claims for BPC-157 generally (not made in this post) Partly supported in rodents; not supported in people Mostly one group, injury and drug models [1][17][18]

Frequently asked questions

Has BPC-157 been tested in humans? Three small uncontrolled reports total 30 people, with knee pain, interstitial cystitis and a two-person safety check [9]. A 120-person randomized phase 2 trial in hamstring strain is recruiting, with no results [13].

Does BPC-157 improve cognition? We found no human study of cognition and no healthy-animal test of enhancement. Rodent work reports effects after brain injury or drug challenge, mostly from one group [17][40].

Who wrote most of the BPC-157 research? Sikirić is first or last author on 148 of 234 PubMed records and an author on 176 [1]. Other groups have published on tendon cells, blood vessels and toxicology [32][33][34][35].

Is BPC-157 legal or approved? We found no approved medicine in the US. FDA’s advisory panel voted 8-6, with one abstention, on 23 July 2026 to support compounding eligibility (a law-firm summary of the meeting records the same tally [45]), non-binding; we found no final decision [28]. WADA prohibits it at all times [29]. We did not check EU, UK or German registers.

Sources

  1. NCBI PubMed, search “BPC-157 OR BPC157 OR body protection compound” in title/abstract, run through E-utilities and counted by us (2026-11-08; 234 records). https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157%5Btiab%5D+OR+BPC157%5Btiab%5D+OR+%22body+protection+compound%22%5Btiab%5D
  2. Sikirić P et al., “A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC”, J Physiol Paris (1993). https://pubmed.ncbi.nlm.nih.gov/8298609/
  3. Sikirić P et al., “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia)”, Inflammopharmacology (2006). https://pubmed.ncbi.nlm.nih.gov/17186181/
  4. Sikirić P et al., “Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157”, Curr Med Chem (2012). https://pubmed.ncbi.nlm.nih.gov/22300085/
  5. Sikirić P et al., “New studies with stable gastric pentadecapeptide protecting gastrointestinal tract”, Inflammopharmacology (2024). https://pubmed.ncbi.nlm.nih.gov/38980576/
  6. Lee E, Padgett B, “… of BPC 157 for Multiple Types of Knee Pain” (title shortened; the published title names the route), Altern Ther Health Med (2021). https://pubmed.ncbi.nlm.nih.gov/34324435/
  7. Lee E, Walker C, Ayadi B, “Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study”, Altern Ther Health Med (2024). https://pubmed.ncbi.nlm.nih.gov/39325560/
  8. Lee E, Burgess K, “Safety of … BPC157 in Humans: A Pilot Study” (title shortened; the published title names the route), Altern Ther Health Med (2025). https://pubmed.ncbi.nlm.nih.gov/40131143/
  9. Poolton JT, Minett J, Kazmi A, “Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety”, Acta Orthop Belg (2026-10). https://pubmed.ncbi.nlm.nih.gov/42885452/
  10. Vasireddi N et al., “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review”, HSS J (2025). https://pubmed.ncbi.nlm.nih.gov/40756949/
  11. Mateescu DM et al., “BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers”, Pharmaceutics (2026-05). https://pubmed.ncbi.nlm.nih.gov/42198317/
  12. ClinicalTrials.gov, NCT02637284, “PCO-02 - Safety and Pharmacokinetics Trial” (queried 2026-11-08). https://clinicaltrials.gov/study/NCT02637284
  13. ClinicalTrials.gov, NCT07437547, “BPC 157 for Acute Hamstring Muscle Strain Repair” (queried 2026-11-08). https://clinicaltrials.gov/study/NCT07437547
  14. ClinicalTrials.gov, NCT07803250, “Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery” (queried 2026-11-08). https://clinicaltrials.gov/study/NCT07803250
  15. ClinicalTrials.gov, NCT07752381, peptide gummies study, Parlay Wellness (queried 2026-11-08). https://clinicaltrials.gov/study/NCT07752381
  16. Vukojević J et al., “Pentadecapeptide BPC 157 and the central nervous system”, Neural Regen Res (2022). https://pubmed.ncbi.nlm.nih.gov/34380875/
  17. Vukojević J et al., “The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats”, Brain Behav (2020). https://pubmed.ncbi.nlm.nih.gov/32558293/
  18. Jelovac N et al., “A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine”, Biol Psychiatry (1998). https://pubmed.ncbi.nlm.nih.gov/9547930/
  19. Jelovac N et al., “Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats”, Eur J Pharmacol (1999). https://pubmed.ncbi.nlm.nih.gov/10499368/
  20. Tohyama Y, Sikirić P, Diksic M, “Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain”, Life Sci (2004). https://pubmed.ncbi.nlm.nih.gov/15531385/
  21. Tudor M et al., “Traumatic brain injury in mice and pentadecapeptide BPC 157 effect”, Regul Pept (2010). https://pubmed.ncbi.nlm.nih.gov/19931318/
  22. Jelińska J et al., “BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase”, Int J Mol Sci (2026). https://pubmed.ncbi.nlm.nih.gov/42278509/
  23. Sikirić P et al., “Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function”, Pharmaceuticals (2023). https://pubmed.ncbi.nlm.nih.gov/37242459/
  24. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (content current as of 2026-04-22). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  25. FDA, “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act” (updated 2026-05-14). https://www.fda.gov/media/94155/download
  26. FDA, “FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026” (introduction and points to consider). https://www.fda.gov/media/193342/download
  27. FDA, “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” (page content dated 2026-08-06; lists materials, shows no vote result). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  28. ABC News, “FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list” (2026-07-23). https://abcnews.com/Health/fda-advisory-committee-votes-add-popular-peptide-bpc/story?id=134913891
  29. World Anti-Doping Agency, “The 2026 Prohibited List” (in force 2026-01-01), read from a copy hosted by SEGAS because wada-ama.org returned no content to us. https://www.segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
  30. openFDA, Drugs@FDA API queries for “BPC” (2026-11-08). https://api.fda.gov/drug/drugsfda.json
  31. Mendias CL, Awan TM, “Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance”, Preprints.org, not peer reviewed (2026-04-24); abstract read through Europe PMC (PPR1182497) because the publisher page returned 403. https://doi.org/10.20944/preprints202604.1748.v1
  32. Hsieh MJ et al., “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation”, J Mol Med (2017). https://pubmed.ncbi.nlm.nih.gov/27847966/
  33. Chang CH et al., “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts”, Molecules (2014). https://pubmed.ncbi.nlm.nih.gov/25415472/
  34. Xu C et al., “Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds”, Regul Toxicol Pharmacol (2020). https://pubmed.ncbi.nlm.nih.gov/32334036/
  35. He L et al., “Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 … in rats and dogs”, Front Pharmacol (2022). https://pubmed.ncbi.nlm.nih.gov/36588717/
  36. Cox HD, Miller GD, Eichner D, “Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H”, Drug Test Anal (2017). https://pubmed.ncbi.nlm.nih.gov/28035768/
  37. Demirtaş H, “BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence”, Int J Mol Sci (2026). https://pubmed.ncbi.nlm.nih.gov/42794771/
  38. Sikirić P et al., “The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt’s test and chronic unpredictable stress in rats”, J Physiol Paris (2000). https://pubmed.ncbi.nlm.nih.gov/10791689/
  39. Sikirić P et al., “Anxiolytic effect of BPC-157, a gastric pentadecapeptide”, Acta Pharmacol Sin (2001). https://pubmed.ncbi.nlm.nih.gov/11742568/
  40. Zemba Cilic A et al., “BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling ‘Negative-Like’ Symptoms of Schizophrenia”, Biomedicines (2022). https://pubmed.ncbi.nlm.nih.gov/35884767/
  41. ABC News, “FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What’s next?” (2026-07-24). https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915
  42. FDA, Warning Letter to Gram Peptides, 721806 (2026-03-31). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
  43. Moiz A, O’Keefe EL, O’Keefe JH, “Dangers of Injectable Peptides and Other Unregulated ‘Biohacking’ Drugs”, Mo Med (2026). https://pubmed.ncbi.nlm.nih.gov/42757290/
  44. @dex7official, “THE ONLY TRUE COGNITIVE ENHANCEMENT TIER LIST (NO COPES EDITION)” (2026-10-20); post text read through the fxtwitter mirror, tier image viewed directly. https://x.com/dex7official/status/2112691493261484516
  45. McDermott Will & Schulte, “PCAC backs majority of peptides in two-day public meeting” (2026-07-27; table of all seven substances and votes). https://www.mcdermottlaw.com/insights/blogs/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/

This article is information, not medical advice.

More in Peptides